

# Prior Authorization Request Form for bempedoic acid (Nexletol), bempedoic acid/ezetimibe (Nexlizet)



**JOHNS HOPKINS**  
M E D I C I N E

JOHNS HOPKINS  
HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

## USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

**FAX Completed Form and  
Applicable Progress Notes to:  
(410) 424-4037**

**Questions?** Contact the Pharmacy Dept at: (888) 819-1043, option 4

**Clinical Documentation must accompany form in order for a determination to be made.**

**Step 1** Please complete patient and physician information (please print):

<p><b>1</b> Patient Name: _____</p> <p>Address: _____</p> <p>Sponsor ID # _____</p> <p>Date of Birth: _____</p>	<p>Physician Name: _____</p> <p>Address: _____</p> <p>Phone #: _____</p> <p>Secure Fax #: _____</p>
---	---

**Step 2** Please complete the clinical assessment:

<p><b>1.</b> Is the requested medication prescribed by a cardiologist, endocrinologist or lipidologist (for example, the provider is certified through the National Lipid Association or similar organization)?</p>	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<p><b>2.</b> Is the patient at high risk for atherosclerotic cardiovascular disease (ASCVD) based on history of clinical (ASCVD), including one or more of the following:</p> <ul style="list-style-type: none"> <li>acute coronary syndrome (ACS),</li> <li>coronary artery disease (CAD),</li> <li>myocardial infarction (MI),</li> <li>stable or unstable angina,</li> <li>coronary or arterial revascularization,</li> <li>stroke,</li> <li>transient ischemic attack (TIA),</li> <li>peripheral artery disease (PAD)?</li> </ul>	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No Proceed to question 3
<p><b>3.</b> Is the patient at high risk for atherosclerotic cardiovascular disease (ASCVD) based on Heterozygous Familial Hypercholesterolemia (HeFH)?</p>	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<p><b>4.</b> Is the patient on concurrent statin therapy at the maximum tolerated dose and has n't reached LDL goals?</p>	<input type="checkbox"/> Yes Proceed to question 9	<input type="checkbox"/> No Proceed to question 5
<p><b>5.</b> Has the patient experienced intolerable and persistent (lasting longer than 2 weeks) muscle symptoms (muscle pain, cramp) with at least 2 statins?</p>	<input type="checkbox"/> Yes Proceed to question 9	<input type="checkbox"/> No Proceed to question 6

## Prior Authorization Request Form for bempedoic acid (Nexletol), bempedoic acid/ezetimibe (Nexlizet)

6. Does the patient have a history of creatine kinase (CK) levels greater than 10x the upper limit of normal (ULN) unrelated to statin use?	<input type="checkbox"/> Yes Proceed to question <b>9</b>	<input type="checkbox"/> No Proceed to question <b>7</b>
7. Does the patient have a history of statin-associated rhabdomyolysis?	<input type="checkbox"/> Yes Proceed to question <b>9</b>	<input type="checkbox"/> No Proceed to question <b>8</b>
8. Does the patient have a contraindication to statin therapy (for example, active liver disease, including unexplained or persistent elevations in hepatic transaminase levels, hypersensitivity, pregnancy)?	<input type="checkbox"/> Yes Proceed to question <b>9</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
9. What is the requested medication?	<input type="checkbox"/> Nexletol - Proceed to question <b>10</b> <input type="checkbox"/> Nexlizet - Proceed to question <b>12</b>	
10. Is the patient taking ezetimibe concurrently?	<input type="checkbox"/> Yes <b>Sign and date below</b>	<input type="checkbox"/> No Proceed to question <b>11</b>
11. Has the patient tried and was able to tolerate an ezetimibe trial of at least 4-6 weeks?	<input type="checkbox"/> Yes <b>STOP</b> Coverage not approved	<input type="checkbox"/> No <b>Sign and date below</b>
12. Is the patient currently taking ezetimibe?	<input type="checkbox"/> Yes Proceed to question <b>13</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
13. Will ezetimibe be discontinued once Nexlizet is started?	<input type="checkbox"/> Yes <b>Sign and date below</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved

**Step  
3**

I certify the above is true to the best of my knowledge. Please sign and date:

\_\_\_\_\_ Prescriber Signature

\_\_\_\_\_ Date

[11 November 2020]

For Internal Use Only	
<input type="checkbox"/> Approved:	Duration of Approval: ____month(s)
<input type="checkbox"/> Denied:	Authorized By:
<input type="checkbox"/> Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: